An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
SARS-CoV-2 infection can cause severe pneumonia (COVID-19). There is evidence that patients with comorbidities are at higher risk of a severe disease course. The role of immunosuppression in the disease course is not clear. In the present report, we first describe two cases of persisting SARS-CoV-2 viraemia with fatal outcome in patients after rituximab therapy.
Chest X‐ray and thoracic CT imaging. Radiographic imaging showed bipulmonal, peripheral ground glass infiltration in both patients, a frequent finding in COVID‐19 pneumonia.
Fig 2
Development of pro‐inflammatory markers during…
Fig 2
Development of pro‐inflammatory markers during disease course. C‐reactive protein (standard value <0·5…
Fig 2
Development of pro‐inflammatory markers during disease course. C‐reactive protein (standard value <0·5 mg/l), IL‐6 (standard value <6 pg/ml) and ferritin (standard value 30–400 µg/l) increased over time. Vertical lines indicate the date of intubation. Detection of SARS‐CoV‐2 viraemia by real‐time PCR. Viral load increased over time in both patients until death. [Colour figure can be viewed at wileyonlinelibrary.com]
Clark E, Guilpain P, Filip IL, Pansu N, Le Bihan C, Cartron G, Tchernonog E, Roubille C, Morquin D, Makinson A, Tuaillon E, Le Moing V.Clark E, et al.Br J Haematol. 2020 Aug;190(3):e154-e156. doi: 10.1111/bjh.16981. Epub 2020 Jul 16.Br J Haematol. 2020.PMID: 32593180Free PMC article.No abstract available.
References
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses . The species severe acute respiratory syndrome‐related coronavirus: classifying 2019‐nCoV and naming it SARS‐CoV‐2. Nat Microbiol. 2020;5:536–44. DOI: 10.1038/s41564-020-0695-z.
-
DOI
-
PMC
-
PubMed
Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid‐19. N Engl J Med. 2020. [Online ahead of print]. DOI: 10.1056/NEJMoa2007621.
-
DOI
-
PMC
-
PubMed
Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis. 2018;18:e217–7. DOI: 10.1016/S1473-3099(18)30127-0.
-
DOI
-
PMC
-
PubMed
Minotti C, Tirelli F, Barbieri E, Giaquinto C, Dona D. How is immunosuppressive status affecting children and adults in SARS‐CoV‐2 infection? A systematic review. J Infect. 2020. [Epub ahead of print]. DOI: 10.1016/j.jinf.2020.04.026.
-
DOI
-
PMC
-
PubMed
Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019‐nCoV) by real‐time RT‐PCR. Euro Surveill. 2020;25:2000045. DOI: 10.2807/1560-7917.ES.2020.25.3.2000045.
-
DOI
-
PMC
-
PubMed